Amphetamine

Global Attention Deficit Hyperactivity Disorder Market Report 2022: Increasing Recognition of Behavioral Therapy Benefits Boosts Sector - ResearchAndMarkets.com

Retrieved on: 
Friday, January 6, 2023
Pharmaceutical, Health, Neurology, Dextroamphetamine, Electronic health record, Amphetamine, Anxiety, Health, Central nervous system, Bipolar disorder, Clonidine, Depression, Brain, Parent, Narcolepsy, CNS, Johnson & Johnson, Growth, Patient, Attention deficit hyperactivity disorder, Speech, Attention, Movement, ADHD, Attention deficit hyperactivity disorder predominantly inattentive, Guanfacine, Antisocial personality disorder, Pharmacy, SNRI, Laika (EHR testing framework), Methylphenidate, Toy, Pharmaceutical industry

Based on drug type, the attention deficit hyperactivity disorder market is categorized into stimulants and non-stimulants.

Key Points: 
  • Based on drug type, the attention deficit hyperactivity disorder market is categorized into stimulants and non-stimulants.
  • The stimulants segment procured the highest revenue share in the attention deficit hyperactivity disorder market in 2021.
  • The retail pharmacy segment recorded the largest revenue share in the attention deficit hyperactivity disorder market in 2021.
  • On the basis of region, the attention deficit hyperactivity disorder market is analyzed across North America, Europe, Asia Pacific, and LAMEA.

One in Two Patients Tested Misuse Prescription Drugs, Finds 10th Annual Quest Diagnostics Health Trends® Report

Retrieved on: 
Monday, December 12, 2022
Drug, Benzodiazepine, Soul food health trends, Physician, DGX, Cocaine, Substance-related disorder, Bias, Female, Drug overdose, Fentanyl, Public health, Health, Patient, Quest Diagnostics, Population Health Management, Cancer, Illegal drug trade, Privacy, Hospital, Therapeutic drug monitoring, NYSE, Diabetes, Asthma, Policy, DTI, Allergy, Lyme disease, COVID-19, Roger Hawkins (drummer), Death, Multimedia, Degenerative disease, Safety, Hepatitis, Database, CDC, Amphetamine, Male, Risk, Pharmaceutical industry, Medical device, Dietary supplement

SECAUCUS, N.J., Dec. 12, 2022 /PRNewswire/ -- Today, Quest Diagnostics (NYSE: DGX) released its latest Health Trends® report, "Drug Misuse in America 2022: A Decade Lost to the Drug Crisis." The report, which harnesses insights from more than 20 million clinical drug tests over 10 years, shows that while progress has been made in the last decade of drug misuse, patients of all ages and both sexes are still at risk.

Key Points: 
  • To access the Health Trends report, visit Quest Diagnostics Newsroom - Health Trends .
  • In 2021, nearly half (49%) of people tested showed evidence of prescription drug misuse, compared to 60% in 2012.
  • "This year's Quest Diagnostics Health Trends Report underscores the deeply entrenched pattern of prescription drug misuse," said report co-author Harvey W. Kaufman, M.D., Senior Medical Director and Head of the Health Trends Research Program for Quest Diagnostics.
  • Quest Diagnostics Health Trends is a series of scientific reports that provide insights into health issues, based on patient laboratory data, to empower better patient care, population health management and public health policy.

Brevi-T Introduces a Bold New Weapon in the Fight Against the Deadly Drug Crisis

Retrieved on: 
Wednesday, November 9, 2022
Infection, Amphetamine, Parent, SAN, Barbiturate, PULSE, Epidemic, Method, Public health, Ecosystem, Bias, Roger Hawkins (drummer), Workplace, Sexual abuse, Substance abuse, Police, Prevalence, Solution, Drug, CEO, Risk management, Pharmaceutical industry, Medical device, Vaccine

SAN DIEGO, Nov. 9, 2022 /PRNewswire-PRWeb/ -- Brevi-T Bio today announced its pioneering drug abuse monitoring, assessment, and evaluation system. The first-of-its-kind ecosystem and action plan for public health management solves the major problems associated with accurately identifying the presence, type, and scale of drug use.

Key Points: 
  • SAN DIEGO, Nov. 9, 2022 /PRNewswire-PRWeb/ -- Brevi-T Bio today announced its pioneering drug abuse monitoring, assessment, and evaluation system.
  • There is growing concern over the introduction and proliferation of new and even more deadly Drugs of Abuse.
  • To respond rapidly to a crisis in its early stages, it's essential to have real-time warnings when drug use patterns are shifting.
  • Unfortunately, significant challenges exist with the tracking of drugs, largely because of the limitations of flawed drug use reporting.

Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
Central nervous system, Company, Report, Research, Growth, GLOBE, FDA, ADHD, Narcolepsy, Review, CNS, Amphetamine, Central nervous system disease, U.S. Securities and Exchange Commission, Forward-looking statement, NASDAQ, Acquisition, Patient, Pharmaceutical industry, Cryptocurrency

PHILADELPHIA, PA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (Vallon or the Company), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended September 30, 2022.

Key Points: 
  • PHILADELPHIA, PA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (Vallon or the Company), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended September 30, 2022.
  • In April 2022, the Company engaged Ladenburg Thalmann & Co. Inc. for an evaluation of strategic alternatives.
  • Net loss was $1.0 million for the quarter ended September 30, 2022.
  • Research and development expenses were $(18,000) and $0.2 million for the three months ended September 30, 2022 and 2021, respectively.

UnitedRx Combats Drug Diversion in Healthcare with New Solution, Cubex®

Retrieved on: 
Tuesday, November 1, 2022
American Securities, Culture, CEO, American Nurses Association, Marketing, Pharmacy, Intermediate Care Facilities for Individuals with Mental Retardation, Substance-related disorder, Hospice, Group, Amphetamine, Technology, Nursing, Patient, Bed, Association, Solution, Health insurance, Medicine, Pharmaceutical industry, I-CubeX

HILLSIDE, Ill., Nov. 1, 2022 /PRNewswire-PRWeb/ -- UnitedRx, the Midwest's largest full-service, independent long-term care pharmacy, is combating drug diversion in skilled nursing facilities with cutting-edge technology such as Cubex®. To ensure that controlled substances are secure, accounted for, and always administered at the correct dosage, the medicine cabinet features extra security and automated logging.

Key Points: 
  • HILLSIDE, Ill., Nov. 1, 2022 /PRNewswire-PRWeb/ -- UnitedRx , the Midwest's largest full-service, independent long-term care pharmacy, is combating drug diversion in skilled nursing facilities with cutting-edge technology such as Cubex.
  • With over 3 million nurses employed in the healthcare industry, this translates to an estimated 300,000 substance abusers.
  • Drugs that may go unnoticed for a long time are also frequently accessible to healthcare practitioners, further adding to the problem of drug diversion among nurses and CNAs.
  • The device, which is used as part of a complete diversion prevention and detection program, prohibits multiple access to drugs.

From 2016 to 2021, over 60 Percent of Patients with Substance Use Disorder Diagnoses Were Male

Retrieved on: 
Tuesday, September 27, 2022
Incidence, COVID-19, Policy, NEW, Population, Speech disorder, Patient, Lists of diseases, Cannabis, Drug, Diagnosis, Amphetamine, Substance use disorder, Health, Comparison, Medical device, Pharmaceutical industry, Lithium

NEW YORK, Sept. 27, 2022 /PRNewswire/ -- In every year of the period 2016-2021, males accounted for 62 to 63 percent of the gender distribution of patients with a substance use disorder diagnosis, while females made up 37 to 38 percent, according to a new white paper from FAIR Health. In every year of the same period, females accounted for 60 to 61 percent of the gender distribution of patients with an overdose diagnosis, while males made up 39 to 40 percent. The white paper, released today, is entitled A Comparison of Substance Use Disorders before and during the COVID-19 Pandemic: A Study of Private Healthcare Claims.

Key Points: 
  • In 2019 and 2021, New Mexico was the state with the highest proportion of patients with a substance use disorder or overdose diagnosis.
  • From 2019 to 2021, Nebraska was the state with the greatest increase in the proportion of patients with a substance use disorder diagnosis.
  • Sixty-five percent of patients who had a substance use disorder or overdose diagnosis in 2021 had a preexisting mental health condition.
  • Psychiatrists' share of substance use disorder claim lines increased 112.4 percent, from 3.9 percent in 2016 to 8.3 percent in 2021.

atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01

Retrieved on: 
Tuesday, September 27, 2022
Adult, Selective serotonin reuptake inhibitor, Therapy, PK, Safety, Amphetamine, Ethics, COVID-19, Infection, Brain, FDA, Addiction, Paroxetine, NEW, Norepinephrine, Senior, Intellectual property, MDMA, Private Securities Litigation Reform Act, HDEC, Hypertension, Stroke, Forward-looking statement, U.S. Securities and Exchange Commission, Public expenditure, Patient, Mental health, List of life sciences, CEO, Dopamine, Therapeutic index, Annual report, Nasdaq, Serotonin, Anxiety, Diagnosis, Cardiovascular disease, Pharmacology, Foundation for the National Institutes of Health, Research, Security (finance), GLOBE, Post-traumatic stress disorder, SEC, National Institute, Sertraline, PTSD, Failure, Depression, Pharmaceutical industry, Medsafe, Health

NEW YORK and BERLIN, Sept. 27, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), which is developing EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for the treatment of post-traumatic stress disorder (PTSD) and other indications, announced today its Phase 1 study has received regulatory and ethics approvals required from Medsafe and HDEC, respectively, to initiate participant enrollment.

Key Points: 
  • Evidence shows that two-thirds of patients either do not respond or have only a partial response to these medications.
  • These modifications are designed to separate the entactogenic effects of MDMA from some of the known side effects, specifically its stimulant-associated effects.
  • Data on MDMA-assisted psychotherapy strongly suggests its potential for the treatment of PTSD, said Glenn Short, Senior Vice President, Early Development of atai Life Sciences.
  • atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.

Crack is Whack, Especially for Drug Detection Dogs

Retrieved on: 
Thursday, September 1, 2022
Cyproheptadine, Heroin, Medicine, Human, Hospital, Veterinary medicine, Serotonin syndrome, Seizure, Restless, Fentanyl, Cat, Illegal drug trade, GiFT, Temperature, Bradycardia, Emergency, Amphetamine, Dog, Methocarbamol, National Association Medical Staff Services, Bird, Anticonvulsant, Ori, Veterinarian, Tremor, PETS, Animal, Pharmacy, Arrest, Methamphetamine, Bear, Toxicology, Hypotension, Narcotic, Poisoning, Naloxone, Ataxia, Cocaine, Hunting, Pharmaceutical industry

MINNEAPOLIS, Sept. 1, 2022 /PRNewswire/ -- It's not unusual for law enforcement to investigate and arrest suspected drug dealers and buyers, and they often use trained police service dogs to assist. Unfortunately, some of these public service animals come into direct contact with dangerous narcotics, requiring immediate medical treatment.  

Key Points: 
  • "Pet Poison Helpline assists service animals that work as detection dogs with police departments, and we advise on the cases at no charge.
  • These dogs, and their handlers, are trained to prevent accidental inhalation or ingestion of illicit drugs, however there are some accidental exposures that do occur."
  • One of Pet Poison Helpline's most severe drug detection dog cases involved Ori, a police service canine from Traverse City, Michigan.
  • "With police service dogs, the officers may know what they're looking for, but they never know what the search dog is going to find.

Psychemedics Corporation Reports Second Quarter 2022 Financial Results and Declares Quarterly Cash Dividend

Retrieved on: 
Tuesday, August 9, 2022
FDA, Paycheck Protection Program, Psychemedics Corporation, Risk, Fentanyl, PMD, GLOBE, Death, R, Private Securities Litigation Reform Act, Growth, Board, Security (finance), Compliance, Government, Income, Benzodiazepine, COVID-19, Company, ERC, School, U.S. Securities and Exchange Commission, Transport, Federal Reserve Bank, NASDAQ, Cocaine, Amphetamine, Board of directors, Record, Insurance, Abuse, Forgiveness, Drug overdose, Online gambling, Management, Video game, Pharmaceutical industry

ACTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the worlds largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2022.

Key Points: 
  • ACTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the worlds largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2022.
  • Similar to last quarter, our earnings performance was better than appears when compared to last years second quarter.
  • Excluding the ERC in last years second quarter, gross margins and profitability, in fact, improved over the second quarter of 2021.
  • Operating expenses for the second quarter of 2022 increased by $0.4 million, or 17%, compared to the second quarter of 2021.

Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, July 28, 2022
Acquisition, Amphetamine, GLOBE, Insurance, Research, Twitter, U.S. Securities and Exchange Commission, Forward-looking statement, PD, CNS, Board, Narcolepsy, NASDAQ, Central nervous system, Report, Review, ADHD, FDA, Company, Method, Board of directors, Patient, LinkedIn, Pharmacokinetics, SEAL, Central nervous system disease, Growth, Pharmaceutical industry

PHILADELPHIA, PA, July 28, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (Vallon or the Company), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended June 30, 2022 and provided a corporate update.

Key Points: 
  • PHILADELPHIA, PA, July 28, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (Vallon or the Company), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today reported its financial results for the quarter ended June 30, 2022 and provided a corporate update.
  • Net loss was $1.8 million for the quarter ended June 30, 2022.
  • Research and development expenses were $0.3 million and $1.2 million for the three months ended June 30, 2022 and 2021, respectively.
  • General and administrative expenses were $1.2 million and $1.1 million for the three months ended June 30, 2022 and 2021, respectively.